

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



邁博藥業

**Mabpharm Limited**  
**迈博药业有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2181)**

**(1) DESIGNATION OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR  
AND  
(2) CHANGES IN COMPOSITION OF THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (each “**Director**” and collectively “**Directors**”) of Mabpharm Limited (the “**Company**”) is pleased to announce that with effect from October 31, 2025:

- (i) Dr. Qian Weizhu, an executive Director, has been appointed as a member of the nomination committee of the Company (“**Nomination Committee**”);
- (ii) Mr. Tao Jing, an executive Director, has ceased to be a member of the Nomination Committee; and
- (iii) Dr. Zhang Yanyun, an independent non-executive director (each “**INED**” and collectively “**INEDs**”), the chairman of the Remuneration Committee of the Company and a member of the Nomination Committee of the Company, has been designated as the lead independent non-executive director (the “**Lead INED**”).

Following the above changes, the Nomination Committee has one director of a different gender. The Nomination Committee comprises two INEDs (namely Mr. Guo Liangzhong and Dr. Zhang Yanyun) and one executive Director (namely Dr. Qian Weizhu). The chairman of the Nomination Committee is Mr. Guo Liangzhong.

The Lead INED will not have a separate or higher level of liability relative to other INEDs. Dr. Zhang Yanyun’s primary responsibility as the Lead INED is to facilitate and strengthen communication (i) among INEDs; (ii) between INEDs and the rest of the Board; and (iii) with shareholders (in particular, minority shareholders).

The above changes were made in response to the amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, which came into effect on July 1, 2025. The Board believes that the above changes can strengthen the effectiveness and diversity of the Board, and further enhance good corporate governance practices across the Company.

By Order of the Board  
**Mabpharm Limited**  
**Jiao Shuge**  
*Chairman*

Hong Kong, October 31, 2025

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.*